Heterotransplantierte, humane Hodenkarzinomzellinien als prädiktives Testsystem für neue Chemotherapiemodalitäten

  • A. Harstrick
  • R. Guba
  • J. Casper
  • D. Reile
  • H.-U. Hemelt
  • H. Poliwoda
  • H.-J. Schmoll
Conference paper

Zusammenfassung

5 etablierte humane embryonale Hodenkarzinomzellinien wurden auf kongenital thymusaplastische Mäuse heterotransplantiert und ihre Sensibilität gegenüber Cisplatin, Bleomycin, Vinblastin, Ifosfamid und THP-Doxorubicin untersucht. Dabei zeigten sich zwischen den Zellinien deutliche Unterschiede. Die beiden Linien H12.1 und 2102 RPmet erwiesen sich als sensibel gegenüber allen untersuchten Substanzen, während die Linien H 12.7, H 23.1 und 2102 EP Resistenzen gegen eine oder mehrere Substanzen aufwiesen. Die fünf Linien eignen sich in einem Zwei-Schritt-Modell mit einem ersten sensitiven Screening-Schritt (H 12.1 und 2102 RPmet) und spezifischerem zweiten Schritt (H 12.7, H 23.1 und 2102 EP) zur detaillierten und ökonomischen Prüfung neuer, beim Hodentumor möglicherweise wirksamer Substanzen.

Abstract

The sensitivity of five established human testicular cancer cell lines to cisplatin, bleomycin, vinblastine, ifosfamide, and THP-doxorubicin was assessed after heterotransplantation to nude mice in vivo. The lines H 12.1 and 2102 RPmet were sensitive to all five drugs, whereas the remaining three lines proved to be resistant to at least one of the drugs. These five cell lines permit the construction of a two-stop testing system with a sensitive first step involving lines H 12.1 and 2102 RPmet and a second more specific step using the remaining three lines for detailed preclinical evaluation of new cytotoxic drugs which are presumed to be active in testicular cancer.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Bosl GJ, Yagoda A, Vogelzang NJ, Whitmore W, Golbey R (1983) VP-16 plus cisplatin salvage chemotherapy for patients with germ cell tumors who fail to achieve a complete remission. Proc AACR Abstr 594Google Scholar
  2. 2.
    Einhorn LH, Williams SD (1979) Combination chemotherapy in disseminated testicular cancer; the Indiana University experience. Sem in Oncol 6: 87–93Google Scholar
  3. 3.
    Fiebig HH, Schuchhardt C, Henss H, Fiedler L, Löhr GW (1984) Comparison of tumor response in nude mice and in the patients. Behring Inst Research Communications 74: 343–352Google Scholar
  4. 4.
    Mortimer J, Bukowski RM, Mentier J, Hewlett JS, Livingstone RB (1982) VP-16-213, Cisplatinum und adriamycin salvage therapy for refractory and/or recurrent nonseminomatous germ cell neoplasms. Ca Chem Pharm 7: 215–218Google Scholar
  5. 5.
    Peckham MJ, Barrett A, Liew KH, Horwich A, Robinson B, Dobbs HJ, McElwain TJ, Hendry WF (1983) The treatment of metastatic germ cell testicular tumors with bleomycin, etoposide and cisplatin (BEP). Br J Ca 47: 613–619CrossRefGoogle Scholar
  6. 6.
    Raghavan D, Heyderman E, Gibbs J, Neville A, Peckham MJ (1981) Functional and morphological aspects of human teratoma xenografts. In: Bastert GB (ed) Thymusaplastic nude mice and rats in clinical oncology, Gustav Fischer Verlag, Stuttgart 439–445Google Scholar
  7. 7.
    Rygaard J, Povlsen CO (1969) Heterotransplantation of a human malignant tumor to a mouse mutant nude. Acta Path Microb Scan 77: 758–760CrossRefGoogle Scholar
  8. 8.
    Sharkey FE, Fogh JM, Hajdu SJ, Fithgerald PJ, Fogh J (1978) Experience in surgical pathology with human tumor growth in the nude mouse. In: Fogh J, Giovanella B (eds) The nude mouse in experimental and clinical research. Academic press, New York 187–213Google Scholar
  9. 9.
    Steel GG, Courtenay VD, Peckham MJ (1983) The response to chemotherapy of a variety of human tumor xenografts. Br J Cancer 47: 1–13PubMedCrossRefGoogle Scholar
  10. 10.
    Trump DL, Hovert L (1985) Etoposide and very high dose cisplatin: salvage therapy for patients with advanced germ cell neoplasms. Cancer Treat Rep 69: 259–261PubMedGoogle Scholar
  11. 11.
    Venditti JM (1983) The National Cancer Institute antitumor drug discovery program, current and future perspective. Cancer Treat Rep 67: 767–772PubMedGoogle Scholar
  12. 12.
    Vugrin D, Withmore WF, Golbey RB (1983) VAB6 combination chemotherapy of disseminated cancer of the testis. Cancer 51: 211–215PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1988

Authors and Affiliations

  • A. Harstrick
  • R. Guba
  • J. Casper
  • D. Reile
  • H.-U. Hemelt
  • H. Poliwoda
  • H.-J. Schmoll

There are no affiliations available

Personalised recommendations